Similar articles

• [Risk of venous thrombosis during postmenopausal estrogen therapy? The reporting system of adverse effects is functioning].

  Buajordet I, Dybwad TB. Buajordet I, et al. Tidsskr Nor Laegeforen. 1997 Aug 10;117(18):2644-5. Tidsskr Nor Laegeforen. 1997. PMID: 9324824 Norwegian. No abstract available.
• [Postmenopausal hormonal substitution and risk of venous thromboembolism. Need for prospective, randomized trials].

  Arnesen H, Qvigstad E. Arnesen H, et al. Tidsskr Nor Laegeforen. 1997 Nov 20;117(28):4064. Tidsskr Nor Laegeforen. 1997. PMID: 9441436 Norwegian. No abstract available.
• [Estrogens and cardiovascular diseases: should current guidelines be changed?].

  Beller F, Theiss W. Beller F, et al. Zentralbl Gynakol. 1994;116(8):441-8. Zentralbl Gynakol. 1994. PMID: 7941812 Review. German.
• [Risk of thromboembolism in contraception and hormone substitution: an update and recommendations].

  van den Brûle F, Gaspard U. van den Brûle F, et al. J Pharm Belg. 2004;59(1):38-40. J Pharm Belg. 2004. PMID: 15129579 Review. French.
• [Effects of hormone replacement treatment of menopause on the risk of venous thromboembolic disease].

  Thery C, Prat A, Asseman P, Bauchart JJ, Michon P, Lesenne M, Jude B. Thery C, et al. Therapie. 1997 May-Jun;52(3):165-8. Therapie. 1997. PMID: 9366099 Review. French.